RenovoRx
RenovoRx is a life science company developing novel targeted oncology therapies based on a local drug-delivery platform to improve therapeutic outcomes for cancer patients. Their proprietary TAMP™ therapy platform ensures precise delivery near tumor sites, potentially minimizing toxicities and improving safety and efficacy. They are actively involved in clinical trials, including a Phase III TIGeR-PaC trial for pancreatic cancer, and hold multiple patents related to their innovative drug delivery systems.
Industries
Nr. of Employees
small (1-50)
RenovoRx
Patents
Products
Occlusion catheter for temporary vessel isolation and localized infusion
A temporary vessel‑occlusion catheter system that isolates local blood flow and enables intra‑arterial infusion of diagnostic or therapeutic agents to selected peripheral vascular sites.
Occlusion catheter for temporary vessel isolation and localized infusion
A temporary vessel‑occlusion catheter system that isolates local blood flow and enables intra‑arterial infusion of diagnostic or therapeutic agents to selected peripheral vascular sites.
Services
Design and operational execution of randomized multicenter Phase III trials, including site enrollment, interim analyses, DMC coordination, and data collection.
Preclinical studies in large‑animal models to evaluate delivery mechanics, tissue penetration, and safety, including imaging and histologic assessments.
Design and operational execution of randomized multicenter Phase III trials, including site enrollment, interim analyses, DMC coordination, and data collection.
Preclinical studies in large‑animal models to evaluate delivery mechanics, tissue penetration, and safety, including imaging and histologic assessments.
Expertise Areas
- Targeted locoregional drug delivery
- Interventional catheter device design
- Drug–device combination product development
- Phase III clinical trial management
Key Technologies
- Localized intra‑arterial (trans‑arterial) micro‑perfusion
- Dual‑balloon occlusion catheter architecture
- Drug–device combination platforms
- Oncolytic virus locoregional delivery (platform adaptation)